65754-04-3

Basic information

• Product Name: 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo- (9CI)
• Synonyms: 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo- (9CI);6-Oxo-1,6-dihydropyrimidine-5-carboxylic acid;4-Hydroxypyrimidine-5-carboxylic acid;6-oxo-1,6-dihydro-5-pyrimidinecarboxylic acid(SALTDATA: FREE);6-oxo-1,6-dihydro-5-pyrimidinecarboxylic acid;4-oxo-1,4-dihydropyriMidine-5-carboxylic acid;4-HydrocypyriMidine-5-carboxylic acid;5-PyriMidinecarboxylic acid, 1,4-dihydro-4-oxo-
• CAS NO: 65754-04-3
• Molecular Formula: C5H4N2O3
• Molecular Weight: 140.09686
• Product Categories: PYRIMIDINE;Heterocycle-Pyrimidine series
• Mol File: 65754-04-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 238 °C (decomp)
• Boiling Point: 364.482°C at 760 mmHg
• Flash Point: 174.233ºC
• Appearance: /
• Density: 1.613g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.639
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.19±0.20(Predicted)
• CAS DataBase Reference: 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo- (9CI)(65754-04-3)
• EPA Substance Registry System: 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo- (9CI)(65754-04-3)

Safety Data

• Hazardous Substances Data: 65754-04-3(Hazardous Substances Data)

Usage

Uses

4-Hydroxypyrimidine-5-carboxylic acid

InChI:InChI=1/C5H4N2O3/c8-4-3(5(9)10)1-6-2-7-4/h1-2H,(H,9,10)(H,6,7,8)

Upstream product

• 38026-46-9 ethyl 4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxilate 
• 51940-64-8 ethyl 2,4-dichloropyrimidine-5-carboxylate 

Relevant articles and documents

-

-

Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation

A compound having the following formula: wherein R3and M are defined herein, and processes therewith.

[3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy]-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists

The present invention relates to novel α 1 -adrenoceptor antagonists of Formula I: STR1 in which: p is 0 or 1;t is 0, 1 or 2;X is O, S or NR 6 (in which R 6 is hydro or (C 1-6)alkyl);Y and Z are independently CH or N;R 1 is hydro, hydroxy, halo, nitro, amino, cyano, (C 1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C 1-6)alkyl, (C 3-6)cycloalkyl, (C 3-6)cycloalkyl (C 1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C 1-4)alkyl, heteroaryl (C 1-4)alkyl, (C 1-6)alkyloxy, (C 3-6)cycloalkyloxy, (C 3-6)cycloalkyl (C 1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C 1-4)alkyloxy or heteroaryl (C 1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano);R 2 is hydro, hydroxy, halo, cyano, (C 1-6)alkyl or (C 1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms);R 3 is -C (O)R 7 (wherein R 7 is (C 1-6)alkyl, (C 3-6)cycloalkyl, di(C 1-4)alkylamino, N-(C 1-4)alkyl-N-(C 1-4)alkyloxyamino, (C 1-4)alkyl((C 1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl);R 4 is halo, hydroxy, cyano, (C 1-6)alkyl or (C 1-6)alkyloxy; andR 5 is (C 1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.